News

Funding a new business venture in ageing research

News

22 Jan 2019

 We’re delighted to be supporting Magnitude Biosciences Limited, a spinout from Durham University’s departments of Biosciences and Physics. The company has launched having gained investment from Saker Capital and the North East Innovation Fund, supported by the European Regional Development Fund (ERDF) and managed by Northstar Ventures. 

It will assist the ageing research industry and academic researchers in testing compounds, such as food additives and drugs, to understand how they slow down or accelerate the ageing process. Carrying out ageing research can be challenging because large sample sizes are required to capture the inherent variability in ageing, with the process taking many years to yield results. To tackle this, Magnitude Biosciences will test on nematode worms, called C.elegans, which are tubular-like organisms just about visible to the human eye without magnification. They are an established method in ageing research due to their short lifespan (two to three weeks) and their size, which allows large quantities to be tested over relatively short study periods. The company has developed an innovative ‘healthspan machine’, which uses small, low cost computers each linked to a camera, to monitor large numbers of nematodes under multiple conditions. 

Dr David Weinkove, from Durham University’s Department of Biosciences,said:

“Ageing research is becoming more and more important in understanding conditions such as Alzheimer’s disease. 

“Our new research methods could help companies discover and develop new drugs or food additives that could improve the amount of time a person spends living a healthy life.

“We are delighted to have received investment from Northstar Ventures and Saker Capital, which will support us in growing our business over the coming year.” 

Alex Buchan, Northstar Ventures Investment Director, said, “We’re delighted to be investing in such an important area of research. The innovative method that’s been developed has great potential in making a real difference in how people will be able to live longer and healthier lives.  We look forward to seeing the impact this makes in the increasingly important ageing sector.

Photo by Gillian Summerill: Magnitude Biosciences team Front left) Craig Manning, David Weinkove, John O’Brien, Boo Virk, Chris Saunter (front right)

Posted By
Alex Buchan

Related Articles

Believe in Ideas. Start your investment journey today.

View our Funds